Zoledronic acid: A review of its use in the treatment of osteoporosis

Drugs and Aging

Volumn 25, Issue 11, 2008, Pages 963-986

  Deeks, Emma D ^a,b   Perry, Caroline M ^a,b  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

^b WOLTERS KLUWER HEALTH   (United States)

Author keywords

Adis drug evaluations; Osteoporosis; Zoledronic acid, therapeutic use

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; ETIDRONIC ACID; IBANDRONIC ACID; PARACETAMOL; PARATHYROID HORMONE; RALOXIFENE; RECLAST; RISEDRONIC ACID; STRONTIUM RANELATE; UNCLASSIFIED DRUG; VITAMIN D; ZOLEDRONIC ACID;

ARTHRALGIA; BACKACHE; BONE DENSITY; BONE NECROSIS; BONE PAIN; BRONCHITIS; CHILL; COUGHING; CREATININE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; EOSINOPHILIA; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEADACHE AND FACIAL PAIN; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HIP FRACTURE; HOT FLUSH; HUMAN; HYPOCALCEMIA; LEG CRAMPS; LOADING DRUG DOSE; MYALGIA; NEPHROTOXICITY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; SINUSITIS; TREATMENT CONTRAINDICATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VENOUS THROMBOEMBOLISM;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HIP FRACTURES; HUMANS; IMIDAZOLES; MALE; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL;

EID: 54549121554     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/0002512-200825110-00007     Document Type: Review

References (91)

1. World Health Organization. Prevention and management of osteoporosis: report of a WHO scientific group. WHO technical report series [online]. Available from URL: http://whqlibdoc.who.int/trs/WHO_TRS_921.pdf [Accessed 2008 Feb 20]
2. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/ professionals/NOF_Clinicians_Guide.pdf [Accessed 2008 Jun 26]
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001 Feb 14; 285 (6): 785-95
4. Scottish Intercollegiate Guideline Network. Management of osteoporosis: a national clinical guideline [online]. Available from URL: http://www.sign.ac.uk [Accessed 2008 Feb 5]
5. Cadarette SM, Katz JN, Brookhart MA, et al. Trends in drug prescribing for osteoporosis after hip fracture, 1995-2004. J Rheumatol 2008 Feb; 35 (2): 319-26
6. Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006 Feb; 28 (2): 151-73.
7. European Medicines Agency. Aclasta: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ aclasta/H-595-PI-en.pdf [Accessed 2008 Oct 23]
8. Food and Drug Administration. Reclast® (zoledronic acid) injection: US prescribing information [online]. Available from URL: http://www.fda.gov/ cder/foi/label/2008/021817s001lbl.pdf [Accessed 2008 Jun 23]
9. European Medicines Agency. Zometa 4mg: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ zometa/H-336-PI-en.pdf [Accessed 2008 Jul 11]
10. Food and Drug Administration. Zometa® (zoledronic acid) injection: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/ foi/label/2008/021223s016lbl.pdf [Accessed 2008 Jul 11]
11. Li EC, Davis LE. Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 2003; 25 (11): 2669-708
12. Keating GM, Scott LJ. Zoledronic acid: a review of its use in the treatment of Paget's disease of bone. Drugs 2007; 67 (5): 793-804
13. Wellington K, Goa KL. Zoledronic acid: a review of its use in the management of bone metastases and hypercalcaemia of malignancy. Drugs 2003; 63 (4): 417-37
14. Perry CM, Figgitt DP. Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 2004; 64 (11): 1197-211
15. Dhillon S, Lyseng-Williamson KA. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 2008; 68 (4): 507-34
16. Russell RGG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci 2006 Apr; 1068: 367-401
17. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 2006 May; 38 (5): 617-27
18. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Clin Pharmacol Exp Ther 2001 Feb; 296 (2): 235-42
19. Coxon FP, Helfrich MH, Van't Hof RJ, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000 Aug 15; 15 (8): 1467-76
20. Fromigué O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J Endocrinol Invest 2002 Jun; 25 (6): 539-46
21. von Knoch F, Jaquiery C, Kowalsky M, et al. Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials 2005 Dec; 26 (34): 6941-9
22. Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci U S A 2006 May 16; 103 (20): 7829-34
23. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May 3; 356 (18): 1809-22
24. McClung M, Recker R, Miller P, et al. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 2007 Jul; 41 (1): 122-8
25. Saag K, Lindsay R, Kriegman A, et al. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density. Bone 2007 May; 40 (5): 1238-43
26. Black DM, Boonen S, Bauer DC, et al. Reduction of bone turnover markers with annual infusion of zoledronic acid 5 mg in postmenopausal osteoporosis: influence of age, renal function, concomitant therapy, and duration of treatment [abstract no. T385]. J Bone Miner Res 2007 Jan 1; 22 Suppl. 1: S328
27. Boonen S, Black DM, Sellmeyer D, et al. The skeletal response to zoledronic acid is not affected by renal impairment: results from the HORIZON-PFT study [abstract no. FRI0377]. Annual European Congress of Rheumatology; 2008 Jun 11-14; Paris
28. Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002 Nov; 42 (11): 1228-36
29. Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003 Feb; 43 (2): 154-62
30. Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res 2008 Jan; 23 (1): 6-16
31. Recker RR, Delmas P, Reid I, et al. The effects of zoledronic acid 5 mg once-yearly on bone remodelling and structure in osteoporotic women are consistent across age [abstract no. S434]. J Bone Miner Res 2007 Jan; 22 Suppl. 1: S129
32. Reid DM, Delmas PD, Bone H, et al. Zoledronic acid reduces fractures and increases BMD with and without concomitant osteoporosis therapy [abstract no. P1-512]. The Endocrine Society's Annual Meeting; 2008 Jun 15-18; San Francisco (CA)
33. Eastell R, Lang T, Delmas PD, et al. Increased integral bone mineral density of the hip with once-yearly zoledronic acid 5 mg: quantitative computed tomography data from the HORIZON-PFT trial [abstract no. FRI0392]. Annual European Congress of Rheumatology; 2008 Jun 11-14; Paris
34. Recker R, Kriegman A, Adera M, et al. Bone histomorphometry demonstrates normal bone remodeling in postmenopausal women with low bone mineral density switched from oral alendronate to IV zoledronic acid [abstract no. 1433]. Arthritis Rheum 2006 Sep; 54 (9 Suppl.): S587. Plus poster presented at the 70th Annual Scientific Meeting of the American College of Rheumatology and the 41st Annual Meeting of the Association of Rheumatology Health Professionals; 2006 Nov 10-15; Washington (DC) 35.
35. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002 Feb 28; 346 (9): 653-61
36. Devogelaer JP, Brown JP, Burckhardt P, et al. Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis. Osteoporos Int 2007 Sep; 18 (9): 1211-8
37. Nieto E, Cerrada L, Salinas J. One year zoledronic acid therapy in primary osteoporosis [abstract no. P794SU]. Osteoporos Int 2006 Jan 1; 18: 6
38. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007 Nov 1; 357 (18): 1799-809
39. Colón-Emeric CS, Caminis J, Suh TT, et al. The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair. Curr Med Res Opin 2004 Jun; 20 (6): 903-10
40. Colón-Emeric CS, Eriksen EF, Lyles KW, et al. Timing of dosing of zoledronic acid 5mg after recent hip fracture affects antifracture efficacy and reduction of mortality: HORIZON-recurrent fracture trial [abstract no. P44]. J Am Geriatrics Society 2008 Apr; 56 (4 Suppl. S1-S238): S17
41. Grbic JT, Landesberg R, Lin SQ, et al. Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial. J Am Dent Assoc 2008 Jan; 139 (1): 32-40
42. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney Int 2008 Sep; 74 (5): 641-8
43. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006 May-Jun; 13 (3): 340-67
44. University of Michigan Health System. Osteoporosis: prevention and treatment. Guidelines for clinical care [online]. Available from URL: http://cme.med.umich.edu/pdf/guideline/osteoporosis05.pdf [Accessed 2008 Feb 5]
45. Atik OS, Gunal I, Korkusuz F. Burden of osteoporosis. Clin Orthop Relat Res 2006 Feb; 443: 19-24
46. Pfeilschifter J. 2006 DVO-guideline for prevention, diagnosis, and therapy of osteoporosis for women after menopause, for men after age 60: executive summary guidelines. Exp Clin Endocrinol Diabetes 2006 Nov; 114 (10): 611-22
47. Sambrook PN, Seeman E, Phillips SR, et al. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Cosponsored by Osteoporosis Australia and the National Prescribing Service. Med J Aust 2002 Apr 15; 176 Suppl.: S1-16
48. Brown JP, Josse RG. Scientific Advisory Council of the Osteoporosis Society of Canada. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ 2002 Nov 12; 167 (10): S1-S34
49. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003 [published erratum appears in Endocr Pract 2004 Jan-Feb;10 (1): 90]. Endocr Pract 2003 Nov-Dec; 9 (6): 544-64
50. Licata AA. Update on therapy for osteoporosis. Orthop Nurs 2007 May-Jun; 26 (3): 162-6
51. Burlet N, Reginster J-Y. Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis. Clin Orthop Relat Res 2006 Feb; 443: 55-60
52. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005 Dec; 115 (12): 3318-25
53. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005 Apr; 27 (4): 361-76
54. European Medicines Agency. Bonviva: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ Bonviva/H-501-PI-en.pdf [Accessed 2008 Apr 7]
55. Food and Drug Administration. Boniva® (ibandronate sodium) injection: US prescribing information [online]. Available from URL: http://www.fda.gov./ cder/foi/label/2006/02185s0011bl.pdf [Accessed 2008 Feb 29]
56. Food and Drug Administration. Fosamax® (alendronate sodium) tablets and oral solution [online]. Available from URL: http://www.fda.gov/cder/foi/ label/2006/020560s47s48,021575s10s11,021762s2s3lbl.pdf [Accessed 2008 Apr 7]
57. European Medicines Agency. Fosavance 70 mg/2800 IU tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Fosavance/H-619-PI-en.pdf [Accessed 2008 Apr 7]
58. Food and Drug Administration. Actonel (risedronate sodium) tablet, film coated: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/020835s028lbl.pdf [Accessed 2008 Mar 10]
59. Electronic Medicines Compendium. Actonel 5mg film coated tablets: summary of product characteristics [online]. Available from URL: http://emc.medicines. org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=3340 [Accessed 2008 Apr 7]
60. Electronic Medicines Compendium. Actonel once a week 35mg film coated tablets: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp? documentid=11591 [Accessed 2008 Apr 7]
61. Food and Drug Administration. Supplement approval [online]. Available from URL: http://www.fda.gov/cder/foi/appletter/2008/020835s029,%20s030ltr.pdf [Accessed 2008 Jul 30]
62. Food and Drug Administration. Boniva® (ibandronate sodium) tablets [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/ 021455s005lbl.pdf [Accessed 2008 Apr 7]
63. Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 2006 Jun; 40 (6): 1143-50
64. Food and Drug Administration. Evista® (raloxifene hydrochloride) tablets [online]. Available from URL: http://www.fda.gov/cder/foi/label/2007/ 020815s018lbl.pdf [Accessed 2008 Feb 29]
65. European Medicines Agency. Evista 60 mg film coated tablets: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Evista/H-184-PI-en.pdf [Accessed 2008 Feb 29]
66. Food and Drug Administration. Forteo® teriparatide (rDNA fibrillaorigin) injection 750 mcg/3 mL: US prescribing information [online]. Available from URL: http://www.fda.gov/cder/foi/label/2008/021318s015lbl.pdf [Accessed 2008 Apr 7]
67. European Medicines Agency. Forsteo 20 micrograms/80 microliters: summary of product characteristics [online]. Available from URL: http://www.emea.europa. eu/humandocs/PDFs/EPAR/forsteo/H-425-PI-en.pdf [Accessed 2008 Apr 7]
68. European Medicines Agency. Preotact: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ preotact/H-659-PI-en.pdf [Accessed 2008 Apr 7]
69. European Medicines Agency. Protelos: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ protelos/H-560-PI-en.pdf [Accessed 2008 Apr 7]
70. European Medicines Agency. Osseor: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/ osseor/H-561-PI-en.pdf [Accessed 2008 Apr 11]
71. Cranney A. Treatment of postmenopausal osteoporosis. BMJ 2003 Aug 16; 327: 355-6
72. Lakatos P, Christiansen C, Marton I. New Europe: consensus on osteoporosis 2003. Developed by the 2nd Central and Eastern European Regional Osteoporosis Meeting [online]. Available from URL: http://www.iofbonehealth.org/ download/osteofound/filemanager/policy_advocacy/pdf/lacrima.pdf [Accessed 2008 Feb 21]
73. Scottish Medicines Consortium. 447 08 zoledronic acid 5mg solution [online]. Available from URL: http://www.scottishmedicines.org.uk/smc/5865.html [Accessed 2008 Apr 9]
74. US National Institute of Health. Double-blind extension of HORIZON Pivotal Fracture Trial (zoledronic acid in the treatment of postmenopausal osteoporosis) [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Feb 25]
75. Jansen JP, Olson M, Chan W, et al. Efficacy of zoledronic acid relative to other bisphosphonates for prevention of fractures in osteoporosis: results of a Bayesian mixed treatment comparison [abstract no. P1-513]. The Endocrine Society's Annual Meeting; 2008 Jun 15-18; San Francisco (CA)
76. McCombs JS, Thiebaud P, McLaughlin-Miley C, et al. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004 Jul 15; 48 (3): 271-87
77. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006 Aug; 81 (8): 1013-22
78. Tosteson ANA, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med 2003 Aug 15; 115 (3): 209-16
79. US National Institute of Health. Zoledronic acid in the prevention of bone loss in postmenopausal women with osteopenia, 45 years of age and older [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2008 Feb 25]
80. Food and Drug Administration. Information on bisphosphonates (marketed as Actonel, Actonel+Ca, Aredia, Boniva, Didronel, Fosamax, Fosamax+D, Reclast, Skelid, and Zometa [online]. Available from URL: http://www.fda.gov/cder/drug/ infopage/bisphosphonates/default.htm [Accessed 2008 Apr 3]
81. Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines. Drug safety update: latest advice for medicines users. Bisphosphonates: atrial fibrillation. 2008 Jul; 1 (12): 4
82. Poole KE, Kaptoge S, Reeve J. Yearly zoledronic acid in postmenopausal osteoporosis [letter]. N Engl J Med 2007 Aug 16; 357 (7): 711-2
83. de Nijs RN, Westgeest AA. Yearly zoledronic acid in postmenopausal osteoporosis [letter]. N Engl J Med 2007 Aug 16; 357 (7): 711
84. Black D, Eriksen E, Sellmeyer D. Yearly zoledronic acid in postmenopausal osteoporosis [letter]. N Engl J Med 2007 Aug 16; 357 (7): 714-5
85. Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006 Jun; 17 (6): 897-907
86. Woo S-B, Hellstein JW, Kalmar JR. Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006 May 16; 144 (10): 753-61
87. Pazianas M, Miller P, Blumentals WA, et al. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007 Aug; 29 (8): 1548-58
88. Chaiamnuay S, Saag KG. Postmenopausal osteoporosis: what have we learned since the introduction of bisphosphonates? Rev Endocr Metab Disord 2006 Jun; 7 (1-2): 101-12
89. Ott SM. Long-term safety of bisphosphonates. J Clin Endo Metab 2005; 90 (3): 1897-9
90. NHS Regional Drug and Therapeutics Centre. New drug evaluation: zoledronic acid for post-menopausal osteoporsis [online]. Available from URL: http://www.nyrdtc.nhs.uk/docs/nde/NDE_86_Zol_NDE_Final.pdf [Accessed 2008 Apr 1]
91. Olson M, Brereton N, Huels J, et al. Comparison of the cost-effectiveness of zoledronic acid 5mg for the management of post-menopausal osteoporosis in the UK setting [poster no. POS8]. 10th Annual European Congress for the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2007 Oct 20-23; Dublin 2007